Panobinostat

Small molecule

Also known as LBH589

WithdrawnUS approval

Evidence outlook · regulatory status

US approval withdrawn: Multiple Myeloma (FDA, approved 2015-02-23)

The FDA approved this product and later withdrew the approval, so it has no current US approval. Approvals outside the US are listed below. The trials below are the product's evidence history.

Also approved (1)
EU
  • With bortezomib and dexamethasone for adults with relapsed and/or refractory multiple myeloma after at least two prior regimens
Product first approved 2015EMA

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (3)
Multiple Myeloma
Other / comorbidity
NCT04326764 · Goethe University
2018-07-24 – 2023-02-13 · Acute Myeloid Leukaemia (AML), Myelodysplastic Syndromes (MDS)
What this study did
NCT01034163 · Novartis Pharmaceuticals
Run by former owner Novartis
2010-06 – 2012-05 · Hodgkin's Lymphoma
What this study did
Phase 2 (52)
Multiple Myeloma
NCT02506959 · M.D. Anderson Cancer Center
2015-09-14 – 2024-06-03 · Plasma Cell Leukemia, Plasmacytoma, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
What this study did
NCT02654990 · pharmaand GmbH
2016-04-27 – 2022-08-15 · Multiple Myeloma
What this study did
NCT03256045 · University of Washington
2018-02-08 – 2021-02-05 · Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
What this study did
NCT02756663 · Novartis Pharmaceuticals
Run by former owner Novartis
2016-12 – 2021-02 · Multiple Myeloma
What this study did
NCT02722941 · H. Lee Moffitt Cancer Center and Research Institute
2016-06-10 – 2021-01-18 · Multiple Myeloma
What this study did
NCT02290431 · Novartis Pharmaceuticals
Run by former owner Novartis
2014-12-16 – 2018-12-25 · Relapse/Refractory Multiple Myeloma
What this study did
NCT02720510 · Novartis Pharmaceuticals
Run by former owner Novartis
2016-06-14 – 2017-05-22 · Multiple Myeloma
What this study did
NCT01651039 · Ajai Chari
2012-07 – 2016-12-21 · Multiple Myeloma
What this study did
NCT01658241 · Peter MacCallum Cancer Centre, Australia
2012-07-16 – 2015-03-18 · Nodal Lymphoma, Lymphoma With Cutaneous Involvement, Lymphoma in Leukemic Phase, Marrow Involvement With Lymphoma, Multiple Myeloma
What this study did
NCT01083602 · Novartis Pharmaceuticals
Run by former owner Novartis
2010-06 – 2014-02 · Relapsed and Bortezomib Refractory Multiple Myeloma, Refractory Multiple Myeloma, Multiple Myeloma in Relapse
What this study did
NCT00445068 · Novartis Pharmaceuticals
Run by former owner Novartis
2007-04-16 – 2009-12-25 · Multiple Myeloma
What this study did
Other / comorbidity
NCT05725200 · Oslo University Hospital
2022-09-27 – 2040-12-31 · Metastatic Colorectal Cancer
What this study did
NCT03632317 · University of Michigan Rogel Cancer Center
2019-10 – 2025-10 · Glioma, Diffuse Intrinsic Pontine Glioma
What this study did
NCT04897880 · Australian & New Zealand Children's Haematology/Oncology Group
2019-01-09 – 2024-05-08 · Rhabdoid Tumor, Atypical Teratoid/Rhabdoid Tumor, Malignant Rhabdoid Tumor, Recurrent Brain Tumor, Childhood
What this study did
NCT02588339 · H. Lee Moffitt Cancer Center and Research Institute
2016-03-04 – 2021-07-13 · Graft Versus Host Disease, GVHD
What this study did
NCT02961816 · M.D. Anderson Cancer Center
2017-06 – 2021-06 · Lymphoma
What this study did
NCT01261247 · Mayo Clinic
2011-01-17 – 2019-12-02 · Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Hepatosplenic T-cell Lymphoma, Nodal Marginal Zone B-cell Lymphoma, Peripheral T-cell Lymphoma, Post-transplant Lymphoproliferative Disorder, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Small Intestine Lymphoma, Splenic Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia
What this study did
NCT01802879 · Novartis Pharmaceuticals
Run by former owner Novartis
2013-06-24 – 2018-11-19 · Hematologic Neoplasms
What this study did
NCT02518750 · St. Jude Children's Research Hospital
2016-11-23 – 2018-03-11 · Acute Lymphoblastic Leukemia, Lymphoma, Non-Hodgkin's, Leukemia, T-Cell, Leukemia, B-Cell
What this study did
NCT01523834 · Fondazione Italiana Linfomi - ETS
2011-02 – 2017-04 · Diffuse Large B-cell Lymphoma
What this study did
NCT01238692 · Sarit Assouline
2010-11 – 2016-12 · Diffuse Large B Cell Lymphoma
What this study did
NCT01460940 · Ohio State University Comprehensive Cancer Center
2011-10-13 – 2016-11-16 · Adult Lymphocyte Depletion Hodgkin Lymphoma, Adult Lymphocyte Predominant Hodgkin Lymphoma, Adult Mixed Cellularity Hodgkin Lymphoma, Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma, Adult Nodular Sclerosis Hodgkin Lymphoma, Recurrent Adult Hodgkin Lymphoma
What this study did
NCT00978432 · Anne Beaven, MD
2012-02 – 2016-03 · Diffuse Large B-cell Lymphoma
What this study did
NCT01013597 · University of Wisconsin, Madison
2010-01 – 2016-02 · Thyroid Carcinoma
What this study did
NCT00985946 · University of Wisconsin, Madison
2010-05 – 2015-04 · Neuroendocrine Tumors
What this study did
NCT00777049 · Translational Research in Oncology
2009-02 – 2015-04 · Breast Cancer
What this study did
NCT01282476 · Massachusetts General Hospital
2011-06 – 2014-08 · Diffuse Large B Cell Lymphoma
What this study did
NCT00901147 · Singapore General Hospital
2009-11 – 2014-01 · Peripheral T-cell Lymphoma (Not Otherwise Specified), Angioimmunoblastic T-cell Lymphoma, Extranodal NK/T-cell Lymphoma Nasal Type, Enteropathy- Type T-cell Lymphoma, Hepatosplenic T-cell Lymphoma, Anaplastic Large Cell Lymphoma (ALCL) (ALK-1 Negative), Relapsed ALCL (ALK-1 Positive) Post Autologous Transplant
What this study did
NCT00742027 · Novartis Pharmaceuticals
Run by former owner Novartis
2008-09-16 – 2013-08-12 · Classical Hodgkin's Lymphoma
What this study did
NCT00939159 · M.D. Anderson Cancer Center
2009-08 – 2013-06 · Myelodysplastic Syndrome
What this study did
NCT00425555 · Novartis Pharmaceuticals
Run by former owner Novartis
2007-01 – 2013-06 · Cutaneous T-Cell Lymphoma
What this study did
NCT01028313 · SCRI Development Innovations, LLC
— · Chronic Graft-Versus-Host Disease
What this study did
NCT01528501 · Technical University of Munich
2009-06 – 2013-02 · Metastatic Gastric Cancer
What this study did
NCT01136499 · Centre Leon Berard
2010-01 – 2013-01 · Soft Tissue Sarcoma
What this study did
NCT00936611 · Dana-Farber Cancer Institute
2009-07 – 2012-11 · Waldenstrom's Macroglobulinemia
What this study did
NCT01034657 · Novartis Pharmaceuticals
Run by former owner Novartis
2009-11 – 2012-08 · Myelodysplastic Syndrome (MDS)
What this study did
NCT01115036 · Duke University
2010-04 – 2012-04 · Recurrent Glioblastoma
What this study did
NCT00880269 · Novartis Pharmaceuticals
Run by former owner Novartis
2009-08 – 2012-02 · Refractory Leukemia, Acute Myelogenous Leukemia
What this study did
NCT00690677 · Swedish Medical Center
2008-06 – 2011-12 · Colorectal Cancer
What this study did
NCT00931762 · Novartis Pharmaceuticals
Run by former owner Novartis
2009-08-31 – 2011-08-29 · Primary Myelofibrosis, Post-Polycythemia Vera, Post-Essential Thrombocytopenia
What this study did
NCT01090973 · H. Lee Moffitt Cancer Center and Research Institute
2010-03 – 2011-03 · Non-Hodgkin's Lymphoma
What this study did
NCT00594230 · SCRI Development Innovations, LLC
2008-01 – 2011-03 · Myelodysplastic Syndromes (MDS)
What this study did
NCT01056601 · Masonic Cancer Center, University of Minnesota
2010-09 – 2011-02 · Pancreatic Cancer
What this study did
NCT00667862 · Novartis Pharmaceuticals
Run by former owner Novartis
2008-03-18 – 2010-11-05 · Prostate Cancer
What this study did
NCT00723203 · City of Hope Medical Center
2008-04 – 2010-09 · Leukemia
What this study did
NCT00550277 · SCRI Development Innovations, LLC
2008-01 – 2010-06 · Renal Cell Carcinoma
What this study did
NCT00490776 · Novartis Pharmaceuticals
Run by former owner Novartis
2007-07-05 – 2009-09-22 · Cutaneous T-Cell Lymphoma
What this study did
NCT00848523 · Neurological Surgery, P.C.
2008-11 – 2009-04 · Recurrent Malignant Gliomas
What this study did
NCT00699296 · Novartis Pharmaceuticals
Run by former owner Novartis
2008-05 – 2008-12 · Cutaneous T-Cell Lymphoma, Leukemia-Lymphoma, Adult T-Cell
What this study did
Phase 1/2 (27)
Multiple Myeloma
NCT02802163 · H. Lee Moffitt Cancer Center and Research Institute
2017-06 – 2020-12 · Multiple Myeloma
What this study did
NCT01496118 · SCRI Development Innovations, LLC
2011-12 – 2020-12 · Multiple Myeloma
What this study did
NCT00918333 · Mayo Clinic
2009-06 – 2019-07-16 · Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, B-cell Adult Acute Lymphoblastic Leukemia, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Hepatosplenic T-cell Lymphoma, Nodal Marginal Zone B-cell Lymphoma, Post-transplant Lymphoproliferative Disorder, Primary Central Nervous System Non-Hodgkin Lymphoma, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Multiple Myeloma, Splenic Marginal Zone Lymphoma, T-cell Adult Acute Lymphoblastic Leukemia, Waldenström Macroglobulinemia
What this study did
NCT02057640 · Jason Valent
2014-05-22 – 2018-05-15 · Multiple Myeloma, Kahler Disease, Plasma-Cell Myeloma, Myelomatosis
What this study did
NCT02145715 · Prof Jamie Cavenagh
2013-01 – 2016-01 · Multiple Myeloma
What this study did
NCT00743288 · Oncotherapeutics
2008-07 – 2012-12 · Multiple Myeloma
What this study did
NCT00621244 · Novartis Pharmaceuticals
Run by former owner Novartis
2003-03-01 – 2009-12-03 · Lymphoma, Leukemia, Multiple Myeloma
What this study did
Other / comorbidity
NCT06240520 · Erasmus Medical Center
2024-04 – 2025-10 · Hiv
What this study did
NCT02471430 · Massachusetts General Hospital
2016-05 – 2023-12 · HIV Infection
What this study did
NCT03566199 · Sabine Mueller, MD, PhD
2018-05-22 – 2021-03-31 · Diffuse Intrinsic Pontine Glioma
What this study did
NCT00946647 · Novartis Pharmaceuticals
Run by former owner Novartis
2009-12-02 – 2019-04-29 · Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Acute Myeloid Leukemia
What this study did
NCT00840346 · PETHEMA Foundation
2009-09 – 2018-12 · Acute Myeloblastic Leukaemia
What this study did
NCT01693601 · John Mascarenhas
2013-01 – 2018-05-18 · Myelofibrosis
What this study did
NCT01451268 · Johann Wolfgang Goethe University Hospital
2011-01 – 2018-04 · Myelodysplastic Syndrome, Acute Myeloid Leukemia
What this study did
NCT01169636 · M.D. Anderson Cancer Center
2011-01-31 – 2017-05-17 · Hodgkin's Lymphoma
What this study did
NCT00925132 · University of Iowa
2009-12 – 2016-12 · Metastatic Melanoma
What this study did
NCT01111526 · H. Lee Moffitt Cancer Center and Research Institute
2010-04 – 2016-06 · Graft-Versus-Host Disease
What this study did
NCT00859222 · Patrick Y. Wen, MD
2009-03 – 2015-12 · Malignant Glioma
What this study did
NCT01582009 · Roswell Park Cancer Institute
2010-03 – 2015-12 · Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer
What this study did
NCT01298934 · Ronald Hoffman
2009-09 – 2015-07 · Primary Myelofibrosis, Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase, Post-Essential Thrombocythemia Related Myelofibrosis
What this study did
NCT00878436 · NYU Langone Health
2009-06 – 2015-07 · Prostate Cancer, Prostatic Neoplasms
What this study did
NCT00691938 · Washington University School of Medicine
2008-06 – 2014-08 · Leukemia, Myeloid, Acute, Myelodysplastic Syndromes
What this study did
NCT00967044 · M.D. Anderson Cancer Center
2009-11 – 2014-03 · Lymphoma
What this study did
NCT01680094 · University of Aarhus
2012-09 – 2014-01 · HIV Infection
What this study did
NCT01194908 · Emory University
2010-07 – 2014-01 · Breast Cancer, Breast Tumors, Breast Neoplasms
What this study did
NCT01105312 · Alliance for Clinical Trials in Oncology
2010-09 – 2013-09-03 · Breast Cancer
What this study did
NCT00567879 · Novartis Pharmaceuticals
Run by former owner Novartis
2008-04 – 2011-05 · Breast Cancer
What this study did
Phase 1 (62)
Multiple Myeloma
NCT04956302 · Abdullah Khan
2021-09-27 – 2022-06-16 · Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
What this study did
NCT01965353 · Dana-Farber Cancer Institute
2013-10 – 2021-09 · Multiple Myeloma in Relapse
What this study did
NCT03878524 · OHSU Knight Cancer Institute
2020-04-01 – 2020-12-10 · Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8, Anemia, Ann Arbor Stage III Hodgkin Lymphoma, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Castration-Resistant Prostate Carcinoma, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Hematopoietic and Lymphoid System Neoplasm, Locally Advanced Pancreatic Adenocarcinoma, Metastatic Breast Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Pancreatic Adenocarcinoma, Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Primary Myelofibrosis, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Hematologic Malignancy, Recurrent Hodgkin Lymphoma, Recurrent Myelodysplastic Syndrome, Recurrent Myelodysplastic/Myeloproliferative Neoplasm, Recurrent Myeloproliferative Neoplasm, Recurrent Non-Hodgkin Lymphoma, Recurrent Plasma Cell Myeloma, Recurrent Small Lymphocytic Lymphoma, Refractory Acute Lymphoblastic Leukemia, Refractory Acute Myeloid Leukemia, Refractory Chronic Lymphocytic Leukemia, Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Refractory Chronic Myelomonocytic Leukemia, Refractory Hematologic Malignancy, Refractory Hodgkin Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Myelodysplastic Syndrome, Refractory Myelodysplastic/Myeloproliferative Neoplasm, Refractory Non-Hodgkin Lymphoma, Refractory Plasma Cell Myeloma, Refractory Primary Myelofibrosis, Refractory Small Lymphocytic Lymphoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8, Unresectable Pancreatic Adenocarcinoma
What this study did
NCT01301807 · M.D. Anderson Cancer Center
2011-07-28 – 2019-11-07 · Non-Secretory Plasma Cell Myeloma, Plasmacytosis, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
What this study did
NCT01440582 · M.D. Anderson Cancer Center
2013-02-18 – 2019-02-28 · Myeloma
What this study did
NCT00532675 · Novartis Pharmaceuticals
Run by former owner Novartis
2008-04-22 – 2017-11-08 · Multiple Myeloma
What this study did
NCT01549431 · Emory University
2012-01 – 2017-04 · Multiple Myeloma
What this study did
NCT00532389 · Novartis Pharmaceuticals
Run by former owner Novartis
2007-10 – 2013-10 · Multiple Myeloma
What this study did
NCT00891033 · University of Arkansas
2009-04 – 2013-08 · Multiple Myeloma
What this study did
NCT00962507 · City of Hope Medical Center
2009-07 – 2013-01 · Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
What this study did
Other / comorbidity
NCT01245179 · Abdullah Kutlar
2010-11 – 2027-01 · Sickle Cell Disease
What this study did
NCT02717455 · Pediatric Brain Tumor Consortium
2016-06-28 – 2024-03-31 · Glioma
What this study did
NCT04341311 · Dana-Farber Cancer Institute
2020-08-10 – 2024-02-14 · Diffuse Intrinsic Pontine Glioma, Pediatric Brainstem Glioma, Pediatric Brainstem Gliosarcoma, Recurrent, Pediatric Cancer, Pediatric Brain Tumor, Diffuse Glioma
What this study did
NCT04315064 · The University of Texas Health Science Center, Houston
2020-04-21 – 2023-05-02 · Medulloblastoma
What this study did
NCT03982134 · Muhammad Furqan
2019-09 – 2022-05-01 · Melanoma, Non Small Cell Lung Cancer
What this study did
NCT04804709 · Columbia University
2021-07-28 – 2022-03-31 · Diffuse Intrinsic Pontine Glioma, Diffuse Pontine and Thalamic Gliomas, Diffuse Midline Glioma, H3 K27M-Mutant
What this study did
NCT02890069 · Novartis Pharmaceuticals
Run by former owner Novartis
2016-10-14 – 2022-02-22 · Colorectal Cancer, Non-small Cell Lung Carcinoma (Adenocarcinoma), Triple Negative Breast Cancer, Renal Cell Carcinoma
What this study did
NCT01433445 · Novartis Pharmaceuticals
Run by former owner Novartis
2011-11-01 – 2020-06-22 · Idiopathic Myelofibrosis, Post Essential Thrombocythemia Myelofibrosis, Post Polycythemia-Vera Myelofibrosis
What this study did
NCT02032810 · H. Lee Moffitt Cancer Center and Research Institute
2014-01-07 – 2019-09-25 · Melanoma, Skin Cancer
What this study did
NCT01341834 · National Cancer Centre, Singapore
2010-03 – 2018-12 · Nasopharyngeal Carcinoma, Lymphomas, Any EBV+ Solid Tumour
What this study did
NCT01463046 · University of California, San Francisco
2012-01 – 2018-12 · Acute Myeloid Leukemia, Advanced Myelodysplastic Syndrome
What this study did
NCT02676323 · St. Jude Children's Research Hospital
2016-05-03 – 2018-04-09 · Acute Myeloid Leukemia, Myelodysplastic Syndrome
What this study did
NCT01336842 · University of California, Davis
2011-04 – 2017-06 · Solid Tumors, Non-Small Cell Lung Cancer (NSCLC)
What this study did
NCT01065467 · Dana-Farber Cancer Institute
2010-02 – 2017-03-13 · Melanoma, Malignant Melanoma
What this study did
NCT01032148 · Roswell Park Cancer Institute
2009-12 – 2017-01 · Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma
What this study did
NCT01005797 · Medical University of South Carolina
2009-11 – 2017-01 · Renal Cancer, Non Small Cell Lung Cancer (NSCLC), Soft Tissue Sarcoma
What this study did
NCT00878904 · University of California, San Francisco
2009-09-13 – 2016-10-10 · Unspecified Adult Solid Tumor, Protocol Specific
What this study did
NCT01324635 · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
2012-05 – 2016-10 · Recurrent Glioma, High-grade Meningioma, Brain Metastasis
What this study did
NCT01884428 · Armando Santoro, MD
2011-07 – 2015-12 · Hodgkin's Lymphoma
What this study did
NCT01321346 · Therapeutic Advances in Childhood Leukemia Consortium
2011-03 – 2015-10 · Lymphoblastic Leukemia, Acute, Childhood, Myelogenous Leukemia, Acute, Childhood, Hodgkin's Disease, Non-Hodgkin's Lymphoma
What this study did
NCT00907179 · University of Pittsburgh
2009-07 – 2015-07 · Non-Small Cell Lung Cancer
What this study did
NCT01238965 · University of Southern California
2010-10 – 2015-04 · Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IV Colon Cancer, Stage IV Rectal Cancer
What this study did
NCT00738751 · H. Lee Moffitt Cancer Center and Research Institute
2008-11 – 2015-02 · Lung Cancer, Head and Neck Cancer
What this study did
NCT01504776 · Anand Jillella
2011-04 – 2014-09 · Mantle Cell Lymphoma
What this study did
NCT00686218 · City of Hope Medical Center
2008-05 – 2014-08 · Leukemia
What this study did
NCT00997399 · Novartis Pharmaceuticals
Run by former owner Novartis
2010-03 – 2014-06 · Advanced Solid Tumors
What this study did
NCT01613976 · Novartis Pharmaceuticals
Run by former owner Novartis
2012-08 – 2014-05 · Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), Acute Myeloid Leukemia (AML)
What this study did
NCT01242774 · Novartis Pharmaceuticals
Run by former owner Novartis
2010-10 – 2014-05 · Acute Myeloid Leukemia (AML)
What this study did
NCT01007968 · Novartis Pharmaceuticals
Run by former owner Novartis
2010-03 – 2012-11 · Advanced Solid Tumors
What this study did
NCT01055795 · Herbert Hurwitz
2010-03 – 2012-05 · Advanced Solid Tumors
What this study did
NCT01159418 · Southern Europe New Drug Organization
2008-06 – 2012-03 · Advanced Solid Tumors
What this study did
NCT01055483 · Novartis Pharmaceuticals
Run by former owner Novartis
2009-09 – 2012-02 · Acute Myeloid Leukemia
What this study did
NCT00663832 · Novartis Pharmaceuticals
Run by former owner Novartis
2008-02 – 2011-12 · Prostate Cancer
What this study did
NCT00632489 · SCRI Development Innovations, LLC
2008-05 – 2011-07 · Breast Cancer
What this study did
NCT00958022 · Ahmad Tarhini
2009-09 – 2011-06 · Small Cell Lung Cancer
What this study did
NCT00570284 · Novartis Pharmaceuticals
Run by former owner Novartis
2007-11 – 2011-02 · Cancer
What this study did
NCT00993642 · Tulane University Health Sciences Center
2009-09 – 2010-12 · Breast Cancer
What this study did
NCT00823290 · University of Erlangen-Nürnberg Medical School
2009-01 – 2010-12 · Hepatocellular Carcinoma
What this study did
NCT01160731 · Cancer Trials Ireland
2009-11 – 2010-10 · Lung Cancer
What this study did
Phase 4 (1)
Other / comorbidity
CINC424A2X01B Rollover Protocolactive not recruiting
NCT02386800 · Novartis Pharmaceuticals
Run by former owner Novartis
2015-03-05 – 2032-04-05 · Primary Myelofibrosis, Polycythemia Vera, Graft Versus Host Disease, Acute Myeloid Leukemia, Thalassemia
What this study did

Competitive landscape

6 other tracked programmes target this mechanism, 3 of them ahead of this one.

This drug's own stage for Multiple Myeloma: US approval withdrawn. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Panobinostat: this drugUS approval withdrawnSmall moleculeHDACPartial signal
NCT01023308: Progression-free survival (investigator-assessed): median 11.99 months with panobinostat + bortezomib + dexamethasone vs 8.08 months with placebo + bortezomib + dexamethasone; HR 0.63 (95% CI 0.52-0.76), p<0.0001 (Lancet Oncology 2014)
Belantamab MafodotinApprovedAntibody–drug conjugateBCMAPartial signal
NCT04246047: Progression-free Survival (PFS) (Up to approximately 41 months): Belantamab Mafodotin + Bortezomib (Bor) + Dexamethasone (Dex) 36.6 Months vs Daratumumab + Bor + Dex 13.4 Months (95% CI 11.1 to 17.5)
NCT04162210: Progression-Free Survival (PFS) Based on Investigator-Assessed Response as Per International Myeloma Working Group (IMWG) (Up to 27 months): Belantamab Mafodotin 11.2 Months (95% CI 6.4 to 14.5) vs Pomalidomide Plus Dexamethasone 7 Months (95% CI 4.6 to 10.6) missed
BortezomibApprovedSmall moleculeProteasomePartial signal
NCT00722566: Number of Patients With Overall Response (Complete Response + Partial Response) (Over 4 cycles (prior to the addition of dexamethasone)): VELCADE Subcutaneuous 61/145 | VELCADE Intravenous 31/73
NCT00048230: Response rate (CR+PR): 38% bortezomib vs 18% dexamethasone (P<0.001), with CR 6% vs <1%; median time to progression 6.22 vs 3.49 months (HR 0.55, P<0.001); 1-year survival 80% vs 66% (P=0.003), overall survival HR 0.57 (P=0.001).
CarfilzomibApprovedSmall moleculeProteasomePartial signal
NCT03158688: Progression-free Survival (PFS) as Assessed by the Independent Review Committee (PA DCO Only) (From randomization until the PA DCO date of 14 July 2019; the longest treatment duration as of the DCO was 102.3 weeks): Kd - Carfilzomib and Dexamethasone — Participants with PFS events: 68 Participants; Participants who were censored: 86 Participants | KdD - Carfilzomib, Dexamethasone and Daratumumab — Participants with PFS events: 110 Participants; Participants who were censored: 202 Participants
NCT01568866: Progression-free Survival (From randomization until the data cut-off date of 10 November 2014; median follow-up time for PFS was 11.1.and 11.9 months in the bortezomib and carfilzomib arms respectively): Carfilzomib + DEX 18.7 months vs Bortezomib + DEX 9.4 months (95% CI 8.4 to 10.4)
Ciltacabtagene AutoleucelApprovedCell therapyBCMAPartial signal
NCT04181827: Progression-free survival: median not reached with cilta-cel vs 11.8 months with standard care (hazard ratio 0.26; 95% CI 0.18 to 0.38; P<0.001); 12-month PFS 75.9% vs 48.6% (CARTITUDE-4, N Engl J Med 2023).
DaratumumabApprovedMonoclonal antibodyCD38Partial signal
NCT03901963: Percentage of Participants Who Had Minimal Residual Disease (MRD) Conversion From Baseline to 12 Months After Start of Maintenance Treatment as Determined by Next Generation Sequencing (NGS) (From randomization up to 12 months): Daratumumab + Lenalidomide 50.5% (95% CI 40.3 to 60.7) vs Lenalidomide 18.8% (95% CI 11.7 to 27.8)
NCT02076009: Progression-free survival at the interim analysis: hazard ratio 0.37 (95% CI 0.27 to 0.52; P<0.001); 12-month PFS 83.2% with daratumumab plus lenalidomide/dexamethasone vs 60.1% with lenalidomide/dexamethasone (POLLUX, N Engl J Med 2016).
ElotuzumabApprovedMonoclonal antibodySLAMF7 (CS1/CD319)Partial signal
NCT01335399: Progression-Free Survival (PFS) (From randomization to date of first documented tumor progression or death due to any cause (up to 8 years)): E-Ld Cohort 31.38 Months (95% CI 26.18 to 36.8) vs Ld Cohort 29.47 Months (95% CI 23.49 to 34.3) missed
NCT01239797: Median Progression Free Survival (PFS) (From randomization up to 326 events (up to approximately 38 months)): Lenalidomide + Dexamethasone + Elotuzumab 19.35 Months (95% CI 16.62 to 22.18) vs Lenalidomide + Dexamethasone 14.85 Months (95% CI 12.09 to 17.22)
ElranatamabApprovedMultispecific antibodyBCMA x CD3Weak signalFeatured results are non-efficacy only in this race
Givinostat
Approved(overall)
Small moleculeHDAC
Reliable signal(overall)
No reviewed efficacy summary in this indication
Iberdomide (Zenbexus)ApprovedSmall moleculeCereblon E3 ubiquitin-ligasenot yet gradedNo reviewed efficacy summary in this indication
Idecabtagene VicleucelApprovedCell therapyBCMAReliable signal
NCT03651128: PFS 13.3 vs 4.4 mo (HR 0.49 [95% CI 0.38-0.65], p<0.001); ORR 71% vs 42% (p<0.001)
NCT03361748: Overall Response Rate (From first dose to 24 Months): BB2121 74.5% (95% CI 67.1 to 81.8)
IsatuximabApprovedMonoclonal antibodyCD38Partial signal
NCT02990338: Progression Free Survival (PFS) (From the date of randomization to the date of first documentation of progression, or the date of death from any cause, or initiation of further anti-myeloma treatment or data cut-off whichever comes first (maximum duration: 76.7 weeks)): IPd (Isatuximab + Pomalidomide + Dexamethasone) 11.53 months (95% CI 8.936 to 13.897) vs Pd (Pomalidomide + Dexamethasone) 6.47 months (95% CI 4.468 to 8.279)
IxazomibApprovedSmall moleculeProteasomeReliable signal
NCT02312258: Progression Free Survival (PFS) (From randomization until PD or death (up to 52 months)): Ixazomib 17.4 months (95% CI 14.78 to 20.3) vs Placebo 9.4 months (95% CI 8.51 to 11.47)
NCT02181413: Progression Free Survival (PFS) (Randomization up to End of treatment (EOT) (24 months); thereafter followed up every 4 weeks (up to 45 months)): Ixazomib Citrate 26.5 months (95% CI 23.69 to 33.81) vs Placebo 21.3 months (95% CI 17.97 to 24.67)
LenalidomideApprovedSmall moleculeCereblon E3 ubiquitin-ligase, Thalidomide AnalogReliable signal
NCT00424047: Kaplan-Meier Estimate of Time to Tumor Progression (TTP) (From randomization up to cut-off date of 03 August 2005; up to 24 months): Lenalidomide Plus Dexamethasone 52.1 weeks vs Placebo Plus Dexamethasone 20.1 weeks (95% CI 16.6 to 20.7)
NCT00056160: Time to Tumor Progression (TTP) (60 weeks (median Time To Progression of CC-5013/Dex treatment group)): CC-5013/Dex 60.1 Weeks (95% CI 41.1 to 80) vs Placebo/Dex 20.1 Weeks (95% CI 16.1 to 21.1)
LinvoseltamabApprovedMultispecific antibodyBCMA x CD3not yet gradedNo reviewed efficacy summary in this indication
Melphalan Hydrochloride (Evomela)ApprovedSmall moleculeDNA (guanine N7 position)Weak signal
NCT03159702: Progression-free Survival (PFS) of Participants With Hematological Malignancies Undergoing Treatment. (1 year): MEL/FLU and Total-Body Irradiation (TBI) 17/43
MotixafortideApprovedPeptideCXCR4Partial signal
NCT03246529: Proportion of patients who collected at least 6 x 10^6 CD34+ cells/kg in up to 2 aphereses (central laboratory), randomized Part 2, motixafortide + filgrastim (n=80) vs placebo + filgrastim (n=42): 67.5% vs 9.5%, adjusted difference 56.8%, p < 0.0001 (stratified Cochran-Mantel-Haenszel; APHEXDA US label, section 14). CT.gov posted results for the same randomized groups give 70.0% vs 14.3%, p < 0.0001 (Cochran-Mantel-Haenszel).
NCT02639559: Number of Donors That Mobilize ≥ 2 x 10^6 CD34+ Cells/kg of Recipients Weight After a Single Injection of BL-8040 After no More Than Two Leukapheresis Collections (Arm 1 - Donors Only) (Up to Day 2): Arm 1: Donors 22/24
PlerixaforApprovedSmall moleculeCXCR4Partial signal
NCT00103662: Collection of at least 6 x 10^6 CD34+ cells/kg in 2 or fewer aphereses: plerixafor plus G-CSF 71.6% (106/148) vs placebo plus G-CSF 34.4% (53/154), P<.001 (DiPersio et al., Blood 2009).
PomalidomideApprovedSmall moleculeCereblon (CRBN)Partial signal
NCT01324947: Percentage of Participants With an Objective Response According to International Myeloma Working Group (IMWG) Uniform Response Criteria Based on Investigator Assessment (From randomization through the study follow-up phase; up to the data cut-off of 31 July 2014; Maximum time on follow-up was 141.1 weeks.): Pomalidomide 23%
NCT01311687: Progression-free Survival (PFS) - Primary Analysis (From randomization until the data cut-off date of 07 September 2012. Maximum duration of follow-up for PFS assessments was 57 weeks.): Pomalidomide Plus Low-Dose Dexamethasone 15.7 weeks (95% CI 13 to 20.1) vs High-Dose Dexamethasone 8 weeks (95% CI 7 to 9)
Romidepsin
Approved(overall)
Small moleculeHDAC
not yet graded(overall)
No reviewed efficacy summary in this indication
SelinexorApprovedSmall moleculeXPO1 (exportin-1)Partial signal
NCT03110562: SVd/Vd Arm: Progression-free Survival (PFS) as Assessed by Independent Review Committee (IRC) (From date of randomization until IRC-confirmed documented PD or death, censored date, whichever occurred first (up to 33 months)): SVd Arm: Selinexor + Bortezomib + Dexamethasone 13.93 Months vs Vd Arm: Bortezomib + Dexamethasone 9.46 Months (95% CI 8.11 to 10.78)
TalquetamabApprovedMultispecific antibodyGPRC5D x CD3not yet gradedNo reviewed efficacy summary in this indication
TeclistamabApprovedMultispecific antibodyBCMA x CD3Partial signal
NCT05083169: Primary endpoint, progression-free survival: teclistamab plus daratumumab was statistically significant and superior to DPd/DVd (J&J, 2025-10-16).
NCT04696809: Phase 2 primary endpoint ORR 76.9% (>=VGPR 76.9%, >=CR 65.4%) in 26 patients at RP2D 1.5 mg/kg; median follow-up 14.32 months
ThalidomideApprovedSmall moleculeCereblon E3 ubiquitin-ligasePartial signalFeatured results are non-efficacy only in this race
Vorinostat
Approved(overall)
Small moleculeHDAC
not yet graded(overall)
No reviewed efficacy summary in this indication
Zoledronic Acid (Zometa)ApprovedSmall moleculeFarnesyl pyrophosphate synthase (FPPS)not yet gradedNo reviewed efficacy summary in this indication
Anitocabtagene AutoleucelPhase 3Cell therapyBCMAnot yet gradedNo reviewed efficacy summary in this indication
Arlocabtagene AutoleucelPhase 3Cell therapyGPRC5DWeak signalFeatured results are safety only in this race
AZD0120Phase 3Cell therapyBCMA / CD19not yet gradedNo reviewed efficacy summary in this indication
BCD-264Phase 3Monoclonal antibodyCD38not yet gradedNo reviewed efficacy summary in this indication
CevostamabPhase 3Multispecific antibodyFcRH5 (FcRL5) x CD3not yet gradedNo reviewed efficacy summary in this indication
Chidamide
Phase 3(overall)
Small moleculeHDAC
Reliable signal(overall)
No reviewed efficacy summary in this indication
CT-P44Phase 3Monoclonal antibodyCD38not yet gradedNo reviewed efficacy summary in this indication
Denosumab (Xgeva)Phase 3Monoclonal antibodyRANKLReliable signal
NCT01345019: Time to First On-study Skeletal Related Event (From randomization until the primary analysis data cut-off date of 19 July 2016 (per protocol); median time on study was 17.6 and 17.3 months in each treatment group respectively.): Denosumab 695 days vs Zoledronic Acid 730 days (95% CI 504 to 1014)
Equecabtagene AutoleucelPhase 3Cell therapyBCMAnot yet gradedNo reviewed efficacy summary in this indication
EtentamigPhase 3Multispecific antibodyBCMA x CD3Partial signal
NCT06158841: Dual primary endpoints met: objective response rate and progression-free survival vs standard available therapies (PFS HR 0.40, P<0.0001) (AbbVie, 2026-09-03).
F182112Phase 3Multispecific antibodyBCMA x CD3not yet gradedNo reviewed efficacy summary in this indication
FelzartamabPhase 3Monoclonal antibodyCD38Partial signal
NCT03952091: Median PFS: 18·9 months felzartamab+Rd vs 10·4 months Rd (hazard ratio 0·62; p=0·0035)
Gamgertamig (CM336)Phase 3Multispecific antibodyBCMA x CD3not yet gradedNo reviewed efficacy summary in this indication
HLX15Phase 3Monoclonal antibodyCD38not yet gradedNo reviewed efficacy summary in this indication
IBI3003Phase 3Multispecific antibodyGPRC5D x BCMA x CD3not yet gradedNo reviewed efficacy summary in this indication
InobrodibPhase 3Small moleculeCBP/p300 (bromodomain)not yet gradedNo reviewed efficacy summary in this indication
LumrotatugPhase 3Monoclonal antibodyCD38Weak signal
NCT04818372: CM313 phase 1 dose-escalation/expansion (NCT04818372, anti-CD38 mAb, R/R multiple myeloma + marginal zone lymphoma): grade>=3 TEAEs 15/34 (44.1%), no DLTs; ORR 34.5% among 29 evaluable RRMM patients; median PFS 132 days.
MezigdomidePhase 3Small moleculeCereblon E3 ubiquitin-ligasePartial signal
NCT05552976: Primary endpoint, progression-free survival: statistically significant and clinically meaningful improvement vs carfilzomib and dexamethasone (Bristol Myers Squibb, 2026-03-09).
PlitidepsinPhase 3Small moleculeeEF1A2 (eukaryotic translation elongation factor 1-alpha 2)Partial signal
NCT01102426: Progression Free Survival (PFS) as Per Intention-to-treat (ITT) (From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years): Plitidepsin+Dexamethasone 2.6 months (95% CI 1.9 to 3) vs Dexamethasone 1.7 months (95% CI 1.1 to 2)
QL2109Phase 3Monoclonal antibodyCD38not yet gradedNo reviewed efficacy summary in this indication
QLS32015Phase 3Multispecific antibodyGPRC5D x CD3not yet gradedNo reviewed efficacy summary in this indication
QLS4131Phase 3Multispecific antibodyGPRC5D x BCMA x CD3not yet gradedNo reviewed efficacy summary in this indication
RamantamigPhase 3Multispecific antibodyGPRC5D x BCMA x CD3not yet gradedNo reviewed efficacy summary in this indication
SanritatugPhase 3Monoclonal antibodyCD38not yet gradedNo reviewed efficacy summary in this indication
SCTC21CPhase 3Biologic (subtype unspecified)CD38not yet gradedNo reviewed efficacy summary in this indication
TorutamigPhase 3Multispecific antibodyBCMA x CD3not yet gradedNo reviewed efficacy summary in this indication
TQB2934Phase 3Multispecific antibodyBCMA x CD3not yet gradedNo reviewed efficacy summary in this indication
Velinotamig (GR1803)Phase 3Multispecific antibodyBCMA x CD3Weak signalNo reviewed efficacy summary in this indication
VenetoclaxPhase 3Small moleculeBCL-2not yet gradedNo reviewed efficacy summary in this indication
Burixafor (TG-0054)Phase 2Small moleculeCXCR4Weak signal
NCT01458288: Number of Patients Achieving the CD34+ Hematopoietic Stem Cell (HSC) Mobilization Target of ≧2.5×1000000 Cells/kg (1 week): TG-0054 (3.14 mg/kg) 7/7 | TG-0054 (3.14 mg/kg)+G-CSF 5/5
NCT01018979: Primary mobilization success: 2/4 patients in the TG-0054 2.24 mg/kg group (MM 1, NHL 1) vs 1/3 patients in the 3.14 mg/kg group (MM 1); no p-value or confidence interval reported.
CemsidomidePhase 2Small moleculeCereblon E3 ubiquitin-ligasenot yet gradedNo reviewed efficacy summary in this indication
Hrain Anti-BCMA CAR-TPhase 2Cell therapyBCMAWeak signalFeatured results are safety only in this race
HRC0202Phase 2Cell therapyBCMAWeak signalFeatured results are safety only in this race
Iopofosine I-131Phase 2Radiopharmaceuticalphospholipid ether (selective lipid raftWeak signal
NCT02278315: The phase 1 dose-escalation and safety study enrolled 31 patients with relapsed or refractory multiple myeloma who had received a median of four prior lines of therapy. It established 31.25 mCi/m2 as the maximum tolerated single dose and identified 20 mCi/m2 administered twice, one week apart, as the highest evaluated fractionated dose regimen.
LMY-920Phase 2Cell therapyBCMA / TACInot yet gradedNo reviewed efficacy summary in this indication
RAPA-201Phase 2Cell therapyRapamycin-resistant autologous T-cell therapyWeak signal
NCT04176380: Overall response rate: 9/14 patients (64%) achieved disease remission (IMWG criteria) - 8 partial responses, 1 stringent complete response.
YKST02Phase 2Multispecific antibodyBCMA x CD3not yet gradedNo reviewed efficacy summary in this indication
AZD4045Phase 1/2Cell therapyBCMAnot yet gradedNo reviewed efficacy summary in this indication
BCMA CAR-NK (Shenzhen Pregene Biopharma)Phase 1/2Cell therapyBCMAWeak signalNo reviewed efficacy summary in this indication
Purinostat MesylatePhase 1/2Small moleculeHDACnot yet gradedNo reviewed efficacy summary in this indication
REC-2282
Discontinued
Small moleculeHDAC
not yet graded(overall)
No reviewed efficacy summary in this indication

Large race: only the 66 furthest-along competitors are listed; 106 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(3 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Panobinostat to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
Phase 1Sickle Cell DiseaseRecruiting
Est. primary completion 2026-12-31 · NCT01245179 · CT.gov ↗
What to watch
2032 (1)
April 2032 (1)
Phase 4Primary Myelofibrosis, Polycythemia Vera, Graft Versus Host Disease, Acute Myeloid Leukemia, ThalassemiaActive not recruiting
Est. primary completion 2032-04-05 · NCT02386800 · CT.gov ↗
What to watch
2038 (1)
December 2038 (1)
Phase 2Metastatic Colorectal CancerRecruiting
Est. primary completion 2038-12-31 · NCT05725200 · CT.gov ↗
What to watch

See the full readout calendar ↗